



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

25 November 2010  
EMA/HMPC/102303/2008  
Committee on Herbal Medicinal Products (HMPC)

## List of references supporting the assessment of *Cimicifuga racemosa* (L.) Nutt., rhizoma

**This document was valid from 25 November 2010 until March 2018. It is now superseded by a [new version](#) adopted by the HMPC on 27 March 2018 and published on the EMA website.**

**The Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.**

Al-Amier H, Nasr KA, Lück L, Craker LE. Chemotype variation among black cohosh populations. *HortScience* 2005, 40(4): 1032-1033

Amato P, Christophe S, Mellon PL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. *Menopause* 2002, 9(2): 145-150

Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systemic review. *Climacteric* 2007, 10: 23-26

Available at:

<http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133343.pdf>

Bai W, Henneicke-von Zepelin HH, Wang S, Zheng S, Liu J, Zhang Z [et al.]. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. *Maturitas* 2007, 58: 31-41

Bartsch HH, Fischer J [et al.]. AWB mit Remifemin bei Mamma-Ca-Patientinnen mit klimakterischen Beschwerden unter Tamoxifen: Integrierter medizinischer und biometrischer Bericht, Schaper & Brümmer. Data published in Thesis: Juliane Fischer: Cimicifuga racemosa Extrakt (Remifemin®) bei Mamma-Ca-Patientinnen mit klimakterischen Beschwerden unter hormontherapeutischer Behandlung mit Tamoxifen – eine Anwendungsbeobachtung. Albert-Ludwigs-Universität Freiburg i.Br. 2006

Becher H, Henneicke-von Zepelin HH, Schröder-Bernhardi D, Stammwitz U. Pharmakoepidemiologische Kohortenstudie zur Anwendung von Remifemin® / Remifemin® Plus bei Patientinnen mit



Mammakarzinom einschließlich Hormonrezeptor positiver Tumoren. *J Menopause* 2/2005 Abstract Kongress der DGM

Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. *J Clin Epidemiol* 1993, 46(11): 1331-1336

Beral V. Cancer research UK, breast cancer and hormone-replacement therapy in the million women study. *The Lancet* 2003, 362: 419-427

Blaschek W, Ebel S, Hackenthal E, Holzgrabe U, Keller K, Reichling J, Schulz V, editors. *Hagers Enzyklopädie der Drogen und Arzneistoffe*. 6., neu bearbeitete und ergänzte Auflage, Band 4, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 2007, 644-661

Boekhout AH, Beijnen JH, Schellens JHM. Symptoms and treatment in cancer therapy-induced early menopause. *The Oncologist* 2006, 11: 641-654

Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. *Clinical Therapeutics* 2007, 29(2): 230-241

Brattstroem A. Dosisabhängige Überlegenheit eines neu entwickelten Cimicifuga Extraktes (Ze 450). Eine doppelblinde, randomisierte und Placebo kontrollierte klinische Studie bei menopausalen Beschwerden. *Kongressband Phytopharmaka Phytotherapie* 2005, 6

Briese V, Stammwitz U, Friede M, Henneicke-von Zepelin HH. Black cohosh with or without St. John's wort for symptom-specific climacteric treatment – results of a large-scale, controlled, observational study. *Maturitas* 2007, 57: 405-414

Bruno D, Feeney KJ. Management of postmenopausal symptoms in breast cancer survivors. *Seminars in Oncology* 2006, 33: 696-707

Carpenter J. State of the science: hot flashes and cancer. Part 2: Management and future directions. *Oncology Nursing Forum* 2005, 32(5): 969-978

Chlebowski RT, Kim JA, Col NF. Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. *Seminars in Oncology* 2003, 30(6): 776-788

Commission E (Germany), Monographie: Cimicifugae racemosae rhizoma (Cimicifugawurzelstock), BAnz Nr. 43, 02.03.1989

Commission E (Germany), Monographie: Cimicifugae racemosae rhizoma (Cimicifugawurzelstock), Revision (not published), 14 December 1994

Daiber W. Klimakterische Beschwerden: ohne Hormone zum Erfolg, *Ärztliche Praxis, Die Zeitung des Arztes in Klinik und Praxis*, Sonderdruck; XXXV 1983, 65: 1946-1947

Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries, *J Clin Epidemiol* 1993, 46(11): 1323-1330

Davis VL, Jayo MJ, Hardy ML, Ho A, Lee H [et al.]. Effects of black cohosh on mammary tumor development and progression in MMTV-neu transgenic mice. *Proceedings of the AACR* 2003, 44: Abstract 910

Davis VL, Jayo MJ, Ho A, Kotlarczyk MP, Hardy ML [et al.]. Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. *Cancer Research* 2008, 68(20): 8377-8383

- Dixon-Shanies D, Shaikh N. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. *Oncology Reports* 1999, 6: 1383-1387
- Dugoua JJ, Seely D, Perri D, Koren G, Mills E. Safety and efficacy of black cohosh (*Cimicifuga racemosa*) during pregnancy and lactation. *Can J Clin Pharmacol* 2006, 13(3): 257-261
- Einbond LS, Su T, Wu HA, Friedman R, Wang X [et al.]. Gene expression analysis of the mechanisms whereby black cohosh inhibits human breast cancer cell growth. *Anticancer Research* 2007, 27: 697-712
- Einer-Jensen N, Zhao J, Andersen KP, Kristoffersen K. *Cimicifuga* and *Melbrosia* lack oestrogenic effects in mice and rats. *Maturitas* 1996, 25: 149-153
- EMA, HMPC. Assessment of case reports connected to herbal medicinal products containing *Cimicifugae racemosae rhizoma* (Black cohosh, root), EMEA/HMPC/269258/2006 Rev. 1. London, 8 May 2007. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Herbal\\_HMPC\\_assessment\\_report/2010/02/WC500074167.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_HMPC_assessment_report/2010/02/WC500074167.pdf)
- EMA, HMPC. Guideline on the assessment of clinical safety and efficacy in the preparation of community herbal monographs for the well-established and of community herbal monographs / entries to the community list for traditional herbal medicinal products / substances / preparations, EMEA/HMPC/104613/2005, London 7 September 2006. Available at: [http://www.ema.europa.eu/ema/pages/includes/document/open\\_document.jsp?webContentId=WC500003644](http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003644)
- EMA. Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. EMEA/CHMP/021/97 Rev. 1, London 13 October 2005. Available at: [http://www.ema.europa.eu/ema/pages/includes/document/open\\_document.jsp?webContentId=WC500003348](http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003348)
- ESCOP Monographs 2<sup>nd</sup> edition. *Cimicifugae rhizoma* – Black cohosh. European Scientific Cooperative on Phytotherapy, editor. Thieme, Stuttgart 2003, 79-91
- Fischer J. *Cimicifuga racemosa* Extrakt (Remifemin) bei Mamma-Ca-Patientinnen mit klimakterischen Beschwerden unter hormontherapeutischer Behandlung mit Tamoxifen – eine Anwendungsbeobachtung. PhD Thesis, Albert Ludwig Universität Freiburg. 2006
- Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer C, Birkhäuser M. *Cimicifuga racemosa* dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. *Maturitas* 2005, 51: 397-404
- Freudenstein J, Bodinet C. Influence of an isopropanolic aqueous extract of *Cimicifugae racemosae rhizoma* on the proliferation of MCF-7 cells. In: Proceedings of the Twenty-third International LOF-Symposium of Phyto-estrogens. Ghent 1999
- Freudenstein J, Dasenbrock C, Nißlein T. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic *Cimicifuga racemosae* extract. *Cancer Research* 2002, 62: 3448-3452
- Freudenstein J. Addendum to the 6-month oral toxicity study: Calculation of the dosages and the corresponding safety factors in the 6-month oral toxicity study, IBR Project No.: 20-04-0913-90, 1991, 26 September 1997

Georgiev DB, Jordanova E. Phytoestrogens – the alternative approach. *Maturitas* 1997, 27: 213 (abstract P309)

Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y [et al.]. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a Milk Thistle and Black Cohosh product to Rifampin and Clarithromycin. *Journal of Clinical Pharmacology* 2006, 46: 201-213

Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P [et al.]. Effect of milk thistle (*Silybum marianum*) and black cohosh (*Cimicifuga racemosa*) supplementation on digoxin pharmacokinetics in humans. *Drug Metabol Dispos* 2006, 34(1): 69-74

Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB [et al.]. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clinical Pharmacology & Therapeutics* 2005, 77(5): 415-426

Guzman G, Kallwitz ER, Wojewoda C, Chennuri R, Berkes J [et al.]. Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. *Case Reports in Medicine* 2009, Article ID 918156

Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. *JAMA* 1983, 249(13): 1743-1745

Heinemann LHJ, Potthoff P, Schneider HPG. Health and quality of life outcomes, review international versions of the menopause rating scale (MRS) 2003. Available at: <http://www.hqlo.com/content/1/1/28>

Heinemann K, Ruebig A, Potthoff P, Schneider HPG, Heinemann LAJ [et al.]. The Menopause Rating Scale (MRS) scale: A methodological review. *Health and Quality of Life Outcomes* 2004, 2: 45

Heinemann LAJ, DoMinh T, Strelow F, Gerbsch S, Schnitker J [et al.]. The Menopause Rating Scale (MRs) as outcome measure for hormone treatment? A validation study. *Health and Quality of Life Outcomes* 2004, 2: 67

Henneicke-von Zepelin HH, Meden H, Kostev K, Schröder-Bernhardt D, Stammwitz U [et al.]. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. *International Journal of Clinical Pharmacology and Therapeutics* 2007, 45(3): 143-154

Hickey M, Saunders CM, Stuckey BGA. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. *Lancet Oncol* 2005, 6: 687-695

Hillmann E. Final report on the mutagenicity testing Salmonella/Microsome Test (Ames Test). Schaper & Brümmer unpublished study, Project No.: 95-92-1189-90, 1990

Hirschberg AL, Henneicke-von Zepelin HH, Liske E, Friede M. Clinical study of the drug safety of black cohosh on breast epithelial cell proliferation and mammographic breast density in postmenopausal women. Abstracts of free communications 0174. *Climacteric* 2005, 8(2): 128

Jacobson JS, Troxel AB, Evans J, Klaus L, Vahdat L [et al.]. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. *Journal of Clinical Oncology* 2001, 19(10): 2739-2745

Jarry H, Harnischfeger G, Düker E. Untersuchungen zur endokrinen Wirksamkeit von Inhaltsstoffen aus *Cimicifuga racemosa*, 2. In vitro-Bindung von Inhaltsstoffen an Östrogenrezeptoren. *Planta Medica* 1985, 51(4): 316-319

Jarry H, Harnischfeger G. Untersuchungen zur endokrinen Wirksamkeit von Inhaltsstoffen aus *Cimicifuga racemosa*, 1. Einfluß auf die Serumspiegel von Hypophysenhormonen ovariektomierter Ratten. *Planta Medica* 1985, 51(1): 46-49

Kenemans P. Climacteric and postmenopause: definitions, terms and concepts. Available at: <http://www.womanlab.com/english/professionals/menopausalIssues1.htm>

Korn WD. 6-month oral toxicity study with "Remifemin-Granulate" in rats followed by an 8-week recovery period. Schaper & Brümmer, unpublished study, IBR Project No.: 20-04-0913-90, 1991

Kretzschmar G, Nisslein T, Zierau O, Vollmer G. No estrogen-like effects of an isopropanolic extract of rhizoma *Cimicifugae racemosae* on uterus and vena cava of rats after 17 day treatment. *Journal of Steroid Biochemistry & Molecular Biology* 2005, 97: 271-277

Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. *J Clin Endocrinol* 1953, 13: 688-703

Lehmann-Willenbrock E, Riedel HH. Klinische und endokrinologische Untersuchungen zur Therapie ovarieller Ausfallserscheinungen nach Hysterektomie unter Belassung der Adnexe. *Zentbl Gynäkol* 1988, 110: 611-618

Linden Hirschberg A, Edlund M, Svane G, Azavedo E, Skoog L [et al.]. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. *Menopause* 2007, 14: 89-96

Liske E, Boblitz N, Henneicke-von Zepelin HH. Therapie klimakterischer Beschwerden mit *Cimicifuga racemosa* – Daten zur Wirkung und Wirksamkeit aus einer randomisierten kontrollierten Doppelblindstudie. In: Rietbrock, ed, *Phytopharmaka VI Forschung und klinische Anwendung*. Steinkopff, Darmstadt 2000, 247-257

Liske E, Hänggi W, Henneicke-von Zepelin HH, Boblitz N, Wüstenberg P [et al.]. Physiological investigation of a unique extract of black cohosh (*cimicifugae racemosa* rhizoma): A 6-month clinical study demonstrates no systemic estrogenic effect. *Journal of Women's Health & Gender-Based Medicine* 2002, 11: 163-174

Liske E, Boblitz N. Kooperation *Phytopharmaka*: *Cimicifuga racemosa* rhizome. Kooperation *Phytopharmaka* 1999, Aktualisiertes Wissenschaftliches Erkenntnismaterial 1999

Liu ZP, Yu B, Huo JS, Lu CQ, Chen JS. Estrogenic effects of *Cimicifuga racemosa* (Black cohosh) in mice and on estrogen receptors in MCF-7 cells. *J Med Food* 2001, 4(3): 171-178

Löhning AM. Inaugural Dissertation 1999, Conclusion

Look RM, Morris KT, Homer L, Arnold K, Purdy C [et al.]. Randomized controlled trial of Venlafaxine versus Black cohosh as a treatment for menopausal symptoms in women with breast cancer. 2001 ASCO Annual Meeting. Abstract 2973

Lüde S, Török M, Dieterle S, Knapp AC, Kaeufeler R [et al.]. Hepatic effects of *Cimicifuga racemosa* extract in vivo and in vitro. *Cell Mol Life Sci* 2007, 64(21): 2848-2857

Meyer S, Vogt T, Obermann EC, Landthaler M, Karrer S. Cutaneous pseudolymphoma induced by *Cimicifuga racemosa*. *Dermatology* 2007, 214: 94-96

Mielnik J. Extracts of *Cimicifuga racemosa* in the treatment of neurovegetative symptoms in women in the perimenopausal period. *Maturitas* 1997, 27: 215

Minciullo PL, Saija A, Patafi M, Marotta G, Ferlazzo B [et al.]. Muscle damage induced by black cohosh (*Cimicifuga racemosa*). *Phytomedicine* 2006, 13: 115-118

Moyad M. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. *Urology* 2002, 59(4A): 20-33

Munoz GH, Pluchino S. *Cimicifuga racemosa* for the treatment of hot flashes in women surviving breast cancer. *Maturitas* 2003, 44(1): 59-65

Nappi R, Malavasi B, Brundu B, Facchinetti F. Efficacy of *Cimicifuga racemosa* on climacteric complaints: a randomized study versus low-dose transdermal estradiol. *Gynecological Endocrinology* 2005, 20(1): 30-35

Nesselhut T, Liske E. Pharmacological measures in postmenopausal women with an isopropanolic aqueous extract of *Cimicifugae racemosa rhizoma*. *Menopause* 1999, 6(4): 8

Nesselhut T, Schellhase C, Dietrich R, Kuhn W. Untersuchungen zur proliferativen Potenz von Phytopharmaka mit östrogenähnlicher Wirkung bei Mammakarzinomzellen, Abstract des Vortrages von Dr. Nesselhut 8.9.92, Kongreß der Deutschen Gesellschaft für Gynäkologie, Berlin, *Archives of Gynecology and Obstetrics* 1993, 254: 817-818

Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K [et al.]. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy or placebo. *Annals of Internal Medicine* 2006, 145: 869-879

Nißein T, Freudenstein J. Concomitant administration of an isopropanolic extract of black cohosh and tamoxifen in the in vivo tumor model of implanted RUCa-I rat endometrial adenocarcinoma cells. *Toxicology Letters* 2004, 150: 271-275

Obi N, Chang-Claude J, Berger J, Braendle W, Slinger T [et al.]. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study. *Cancer Epidemiol Biomarkers Prev* 2009, 18: 2207-2213

Öktem M, Eroglu D, Karahan HB, Taskintuna N, Kuscu E [et al.]. Black cohosh and Fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. *Advances in Therapy* 2007, 24(2): 448-461

Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J [et al.]. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. *Obstetrics & Gynecology* 2005, 105(5): 1074-1083

Palacio C, Masri G, Mooradian AD. Black cohosh for the management of menopausal symptoms; A systematic review of clinical trials. *Drugs Aging* 2009, 26(1): 23-36

Palacios S, Ferrer-Barriendos J, Parrilla JJ, Castelo-Branco C, Manubens M [et al.]. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale.] *Med Clin (Barc)* 2004, 122(6): 205-211

Patel NM, Derkits RM. Possible increase in liver enzymes secondary to Atorvastatin and black cohosh administration. *Journal of Pharmacy Practice* 2007, 20(4): 341-346

Pethö A. Change-over of a hormone treatment to a herbal gynaecological remedy practicable? *Ärztliche Praxis* 1987, 47: 1551-1553

Pethö A. Umstellung einer Hormonbehandlung auf ein pflanzliches Gynäkologikum möglich?, *Ärztliche Praxis, Die Zeitung des Arztes in Klinik und Praxis* 1987; Sonderdruck XXXIX. Jahrgang Nr. 47: 1551-1553)

- Piersen CE. Phytoestrogens in botanical dietary supplements: implications for cancer. *Integrative Cancer Therapies* 2003, 2(2): 120-138
- Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL [et al.]. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC. *Journal of Clinical Oncology* 2006, 24(18): 2836-2841
- Pockaj BA, Loprinzi CL, Sloan JA, Novotny PJ, Barton DL [et al.]. Pilot evaluation of black cohosh for the treatment of hot flashes in women. *Cancer Investigation* 2004, 22(4): 515-521
- Raus K, Brucker C, Gorkow C, Wuttke W. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. *Menopause* 2006, 13(4): 678-691
- Rebeck TR, Troxel AB, Norman S, Bunin GR, DeMichele A [et al.]. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. *International Journal of Cancer* 2007, 120(7): 1523-1528
- Reed SD, Newton KM, LaCrois AZ, Grothaus LC, Grieco V [et al.]. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. *Menopause* 2008, 15: 51-58
- Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. *Breast Cancer Research and Treatment* 2005, 90: 233-239
- Ruhlen RL, Haubner J, Tracy JK, Zhu W, Ehya H [et al.]. Black cohosh does not exert an estrogenic effect on the breast. *Nutrition and Cancer* 2007, 59(2): 269-277
- Sakurai N, Kozuka M, Tokuda H, Nobukuni Y, Takayasu J [et al.]. Antitumor agents 220. Antitumor-promoting effects of cimigenol and related compounds on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis. *Bioorganic & Medicinal Chemistry* 2003, 11: 1137-1140
- Schmidt M, Polasek W, Kaeufeler R. Efficacy and Safety of Black Cohosh (Cimicifuga racemosa, Cimifemin) in Menopause. Discomfort: surveillance study in practical terms. *Journal für Menopause* 2005, 12(1): 27-32
- Schneider HPG, Rosemeier HP, Schnitker J, Gerbsch S, Turck R. Application and factor analysis of the menopause rating scale [MRS] in a post-marketing surveillance study of Climen. *Maturitas* 2000, 37: 113-124
- Schneider HPG, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. *Climacteric* 2000, 3: 50-58
- Seidlová-Wuttke D, Jarry H, Becker T, Christoffel V, Wuttke W. Pharmacology of Cimicifuga racemosa extract BNO 1055 in rats: bone, fat and uterus. *Maturitas* 2003, 44(1): 39-50
- Simpson B. Hot flash pharmacotherapy in breast cancer survivors: a literature review. *CPJ/RPC* 2004, 137(3): 36-45
- Spangler L, Newton KM, Grothaus LC, Reed SD, Ehrlich K [et al.]. The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin. *Maturitas* 2007, 57: 195-204
- Stoll W. Phytotherapeutikum beeinflusst atrophisches Vaginalepithel [Phytopharmakon influences atrophic vaginal epithelium. Double blind study – Cimicifuga vs. estrogenic substances.]. *Tpk Therapeutikon Sonderdruck Heft* 1987, 1: 2-15

Stoll W. Englische Fassung. Heft 1, 1987, 2-5

Stolze H. Der andere Weg, klimakterische Beschwerden zu behandeln. [An alternative to treat menopausal complaints.] *Gyne, Fachzeitung für praktische Frauenheilkunde und allgemeine Medizin* 1/82; Sonderdruck Januar 1982

Teschke R, Bahre R, Fuchs J, Wolff A. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. *Menopause* 2009, 16(5): 956-965

Teschke R, Schwarzenboeck A. Suspected hepatotoxicity by *Cimicifugae racemosae rhizoma* (black cohosh, root): critical analysis and structured causality assessment. *Phytomedicine* 2009, 16: 72-84

Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. *Br J Clin Pharmacol* 2008, 66(6): 758-766

USP 32, The United States Pharmacopeia NF 27, Vol. 1, The National Formulary, Black Cohosh, 32. Revision 2009, 986-990

von Schoultz B, Henneicke-von Zepelin HH, Liske E, Friede M, Hirschberg A. Klinische Studie zur Arzneimittelsicherheit von Remifemin® hinsichtlich Brustepithelzell-Proliferation und mammographischer Brustgewebisdichte bei postmenopausalen Frauen. Kongress der Deutschen Menopause Gesellschaft 2005; 17. und 18. Juni 2005, Münster

Vorberg G. Therapie klimakterischer Beschwerden. *ZFA, Zeitschrift für Allgemeinmedizin* 1984, 60(13): 626-629

Walji R, Boon H, Guns E, Oneschuk D, Younus J. Black cohosh (*Cimicifuga racemosa* [L.] Nutt.): safety and efficacy for cancer patients. *Support Care Cancer* 2007, 15: 913-921

Warnecke G. Beeinflussung klimakterischer Beschwerden durch ein Phytotherapeutikum. *Med Welt* 1985, 36: 871-874

Wuttke W, Gorkow C, Seidlova-Wuttke D. Effects of black cohosh (*Cimicifuga racemosa*) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. *Menopause* 2006, 13(2): 185-196

Wuttke W, Seidlova-Wuttke D, Gorkow C. The *Cimicifuga* preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. *Maturitas* 2003, 44(1): 67-77

Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. *P.S.E.B.M.* 1998, 217: 369-378

#### **References read but not included in the Assessment Report**

Al-Akoum, Mahèra, Dodin S, Akoum A. Synergistic cytotoxic effects of tamoxifen and black cohosh on MCF-7 and MDA-MB-231 human breast cancer cells: an in vitro study. *NRC Canada* 2007, 85: 1153-1159

Albertazzi P. Non estrogenic approaches for the treatment of climacteric symptoms. *Climacteric* 2007, 10(2): 115-120

Alves LA, Lima SMRR, da Silva CR, Galvao MAL, Shanaider A [et al.]. Effects of *Trifolium pratense* and *Cimicifuga racemosa* on the endometrium of wistar rats. *Maturitas* 2008, 61: 364-370

Amato P, Marcus DM. Review of alternative therapies for treatment of menopausal symptoms. *Climacteric* 2003, 6: 278-284



Avula B, Wang YH, Smilie T, Khan IA. Quantitative determination of triterpenoids and formononetin in rhizomes of black cohosh (*Actaea Racemosa*) and dietary supplements by sing UPLC-UV/ELS detection and identification by UPLC-MS. *Planta Med* 2009, 75: 381-386

Berger MR. Gutachten zum Tiermodell der FVB/N Maus mit dem Transgen MMTV-neu und Hypothese zum Pathomechanismus der erhöhten Inzidenz von Lungenmetastasen bei diesem Modell nach Applikation von *Cimicifuga racemosa*. Prof. Dr. Martin R. Berger, Deutsches Krebsforschungszentrum Heidelberg 2009

Betz JM, Anderson L, Avigan MI, Barnes J, Farnsworth NR [et al.]. Black Cohosh, considerations of safety and benefit. *Nutrition Today* 2009, 44(4): 155-162

Beuscher N. *Cimicifuga racemosa* L.- Die Traubensilberkerze, Portrait einer Arzneipflanze. *Z Phytotherapie* 1995, 5: 301-310

Bland J. Position on black cohosh safety. Metagenics, Inc. September 2, 2003

Boblitz N, Liske E, Wüstenberg P. Traubensilberkerze: Wirksamkeit, Wirkung und Sicherheit von *Cimicifuga racemosa* in der Gynäkologie. *Deutsche Apothekerzeitung* 2000, 24: 107-114

Bodinet C, Freudenstein J. Influence of *Cimicifuga racemosa* on the proliferation of estrogen receptor-positive human breast cancer cells. *Breast Cancer Research and Treatment* 2002, 76: 1-10

Bodinet C, Freudenstein J. Influence of marketed herbal menopause preparations on MCF-7 cell proliferation. *Menopause* 2004, 11(3): 281-289

Bolle P, Mastrangelo S, Perrone F, Evandri MG. Estrogen-like effect of a *Cimicifuga racemosa* extract subfraction as assessed by in vivo, ex vivo and in vitro assays. *The Journal of Steroid Biochemistry & Molecular Biology* 2007, 107: 262-269

Borrelli F, Izzo AA, Ernst E. Pharmacological effects of *Cimicifuga racemosa*. *Life Science* 2003, 73: 1215-1229

Borelli F, Ernst E. *Cimicifuga racemosa*: a systematic review of its clinical efficacy. *Eur J Clin Pharmacol* 2002, 58: 235-241

Brewer D, Nashelsky J, Hansen LB. Clinical inquiries. What nonhormonal therapies are effective for postmenopausal vasomotor symptoms? *The Journal of Family Practice* 2003, 52(4): 324-5, 329

Briese V, Stammwitz U, Friede M, Henneicke-von Zepelin HH. Wechseljahrestherapie ohne Hormone; Ergebnisse einer aktuellen Anwendungsbeobachtung, Kongress der Deutschen Menopause Gesellschaft 2005; 17. und 18. Juni 2005, Münster – Freie Vorträge und Poster

Bruggisser R, von Daeniken K, Jundt G, Schaffner W, Tullbert-Reinert H. Interference of plant extracts, phytoestrogens and antioxidants with the MTT tetrazolium assay. *Planta Medica* 2002, 68: 445-448

Burckhardt P. Selective Estrogen Receptor Modulators (SERM): neue Substanzen für die Hormonersatztherapie. *Schweiz Med Wochenschr* 1999, 129: 1926-1930

Burdette JE, Liu J, Chen SN, Fabricant DS, Piersen CE [et al.]. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. *Journal of Agricultural and Food Chemistry* 2003, 51: 5661-5670

Carroll DG. Nonhormonal therapies for hot flashes in menopause. *American Family Physician* 2006, 73(3): 457-464

- Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. *Archives of Gynecology and Obstetrics* 2007, 276: 463-469
- Chow EC-Y, Teo M, Ring JA, Chen JW. Live failure associated with the use of black cohosh for menopausal symptoms. *MJA* 2008, 118(7): 420-422
- Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. *Menopause* 2004, 11(5): 575-577
- Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition. *Arch Gen Psychiatry* 2006, 63: 385-390
- Conner P. Hormone therapy and the breast – aspects on proliferation, apoptosis and mammographic density. Karolinska Institute 2004
- Doyle BJ, Mahady GB. Phytomedicines for menopause. *Drugs of the Future* 2007, 32(10): 897-905
- Einbond LS, Shimizu M, Ma H, Wu H, Goldsberry S [et al.]. Actein inhibits the Na<sup>+</sup>-K<sup>+</sup>-ATPase and enhances the growth inhibitory effect of digitoxin on human breast cancer cells. *Biochemical and Biophysical Research Communications* 2008, 375: 608-613
- Einbond LS, Shimizu M, Xiao D, Nuntanakorn P, Lim JTE [et al.]. Growth inhibitory activity of extracts and purified components of black cohosh on human breast cancer cells. *Breast Cancer Research and Treatment* 2003, 2785(3): 1-11
- Einbond LS, Shimizu M, Nuntanakorn P, Seter C, Cheng R [et al.]. Actein and a fraction of black cohosh potentiate antiproliferative effects of chemotherapy agents on human breast cancer cells. *Planta Med* 2006, 72: 1200-1206
- Einbond LS, Su T, Friedman R, Wang X, Ramirez A [et al.]. The growth inhibitory effect of actein on human breast cancer cells is associated with activation of stress response pathways. *International Journal of Cancer* 2007, 121(9): 2073-2083
- EMA. EMEA public statement on recent publications regarding hormone replacement therapy. EMEA/33065/03. London, 3 December 2003
- Ensrud KE, Stone KL, Blackwell TL, Sawaya GF, Tagliaferri M [et al.]. Frequency and severity of hot flashes and sleep disturbance in postmenopausal women with hot flashes 2009, 16: 286-292
- Es-Saady D, Simon A, Jayat-Vignoles C, Chulia AJ, Delage C. MCF-7 Cell Cycle Arrested at G1 Through Ursolic Acid, and increased Reduction of Tetrazolium Salts. *Anticancer Research* 1996, 16: 481-486
- FDA. Guidance for Industry Estrogen and Estrogen/Progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms – recommendations for clinical evaluation. DRAFT. Center for drug evaluation and research US department of health and human services. Food and Drug Administration Clinical/Medical, January 2003
- Fitzpatrick LA. Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal woman. *Mayo Clin Proc* 1999, 74: 601-607
- Freeman EW, Sammel MD, Lin H. Temporal associations of hot flashes and depression in the transition to menopause. *Menopause* 2009, 16(4): 728-734
- Frempong W, Kiuru A, Ericsson J, Farah M. *Cimicifuga racemosa* L. Nutt. (Black cohosh) and anaphylactic reactions, including face and oral oedema. WHO - The Uppsala Monitoring Centre. Available at: <http://www.who-umc.org/graphics/6998.pdf>

- Garita-Hernandez M, Calzado MA, Caballero FJ, Macho A, Munoz E [et al.]. The growth inhibitory activity of the cimicifuga racemosa extract ZE 450 is mediated through estrogen and progesterone receptors-independent pathways. *Planta Med* 2006, 72: 317-323
- Gaube F, Wolf S, Pusch L, Kroll TC, Hamburger M. Gene expression profiling reveals effects of Cimicifuga racemosa (L.) NUTT. (black cohosh) on the estrogen receptor positive human breast cancer cell line MCF-7. *BMC Pharmacology* 2007, 7: 11
- Geller SE, Studee L. Botanical and dietary supplements for mood and anxiety in menopausal women. *Menopause* 2007, 14(3): 541-549
- Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y [et al.]. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. *Menopause* 2009, 16(6): 1-11
- Geller SE, Studee L. Contemporary alternatives to plant estrogens for menopause. *Maturitas* 2006, 55(1): 3-13
- Geller SE. Botanical and dietary supplements for menopausal symptoms: what works, what doesn't. *J Womens Health (Larchmt)* 2005, 14(7): 634-649
- Gori L, Firenzuoli F. Is black cohosh a hepatotoxic medicinal herb? *Forschende Komplementär-medicin* 2007, 17: 109-110
- Guideline. Abklärung von postmenopausalen Blutungen (PMPB). *Schweizerische Ärztezeitung* 2002, Version 2 2002; 83(Nr 45)
- Haimov-Kochmann R, Hochner-Celnikier D. Hot flashes revisited: pharmacological and herbal options for hot flashes management. What does the evidence tell us? *Acta Obstetrica et Gynecologica Scandinavica* 2005, 84: 972-979
- Hanna K, Day A, O'Neill S, Patterson C, Lyons-Wall P. Does scientific evidence support the use of non-prescription supplements for treatment of acute menopausal symptoms such as hot flashes? *Nutrition & Dietetics* 2005, 62: 4
- Harbeck N, Jakesz R. St. Gallen 2007: Breast cancer treatment consensus report. *Breast Care* 2007, 2: 130-134
- Haynes B, Dowsett M. Clinical pharmacology of selective estrogen receptor modulators. *Drug & Aging* 1999, 5: 323-336
- Hays J, Ockene JK, Brunner DR, Kotchen J, Manson JE [et al.]. Effects of Estrogen plus Progestin on Health-related Quality of Life. *The New England Journal of Medicine* 2003, 348: 1839-1854
- Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. *Ann Med* 2001, 33: 350-357
- Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy. *JAMA* 2002, 287(5): 591-597
- Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Evaluation of Cell Death Caused by Triterpene Glycosides and Phenolic Substances from cimicifuga racemosa Extract in Human MCF-7 Breast Cancer Cells. *Phiol Pharm Bull* 2004, 27: 1970-1975
- Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis. *Breast Cancer Research and Treatment* 2004, 84: 151-160

- Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Inhibitory effect of an isopropanolic extract of black cohosh on the invasiveness of MDA-MB 231 human breast cancer cells. *In vivo* 2007, 21: 349-356
- Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Apoptosis of human prostate androgen-dependent and -independent carcinoma cells induced by an isopropanolic extract of black cohosh involves degradation of cytokeratin (CK) 18. *Anticancer Research* 2005, 25: 139-148
- Huntley A, Ernst E. A systematic review of the safety of black cohosh. *Menopause* 2003, 10(1): 58-64
- Huntley A. The safety of black cohosh (*Actaea racemosa*, *Cimicifuga racemosa*). *Expert Opinion Drug Safety* 2004, 3(6): 615-623
- IMS Disease Analyzer. Re-evaluations regarding the REMIFEMIN-study (2004) "study code: SB-FEM 1400"
- Jadad AR. JADAD Score. Available at: [www.ebn.at/cms/dokumente/10089199\\_1486478/68ad7abd/Jadad-Score\\_.pdf](http://www.ebn.at/cms/dokumente/10089199_1486478/68ad7abd/Jadad-Score_.pdf)
- Jarry H, Metten M, Spengler B, Christoffel V, Wuttke W. In vitro effects of the cimicifuga racemosa extract BNO 1055. *Maturitas* 2003, 44: 31-38
- Jarry H, Thelen P, Christoffel V, Spengler B, Wuttke W. Cimicifuga racemosa extract BNO 1055 inhibits proliferation of the human prostate cancer cell line LNCaP. *Phytomedicine* 2005, 12: 178-182
- Jarry H, Stromeier S, Wuttke W, Nahrstedt A. Petasiphenone, a phenol isolated from Cimicifuga racemosa, in vitro inhibits proliferation of the human prostate cancer cell line LNCaP. *Planta Med* 2007, 73: 184-187
- Joy D, Joy J, Duane P. Black cohosh: a cause of abnormal postmenopausal liver function tests. *Climacteric* 2008, 11: 84-88
- Julia Molla MD, Garcia-Sanchez ARS, Perez-Lopez FRP. Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women. *Gynecological Endocrinology* 2009, 25(1): 21-26
- Kaiser WD, Martin R, Schellenberg R, Schrader E, Saller R. Cimicifuga-racemosa-Extrakt ZE 450 bei Wechseljahrsbeschwerden Praxisstudie. *Ars Medici* 2008, 17: 771-774
- Kennelly EJ, Baggett S, Nuntanakorn P, Ososki AL, Mori SA [et al.]. Analysis of thirteen populations of black cohosh for formononetin. *Phytomedicine* 2002, 9: 461-467
- Kok SH, Gambari R, Chui CH, Lau FY, Cheng, GYM [et al.]. Paradoxical proliferative potential of iron (II) sulphate on cancer cells after the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. *International Journal of Molecular Medicine* 2007, 19: 971-975
- Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. *Annals of Internal Medicine* 2002, 137(10): 805-813
- Kruse SO, Löhning A, Pauli GF, Winterhoff H, Nahrstedt A. Fukiic and Piscidic Acid esters from the rhizome of Cimicifuga racemosa and the in vitro estrogenic activity of fukinolic acid. *Planta Med* 1999, 65: 763-764
- Levitsky J, Alli, TA, Wisecarver J, Sorrell MF. Fulminant liver failure associated with the use of black cohosh. *Digestive Diseases and Sciences* 2005, 50(3): 538-539

Liebermann S. A review of the effectiveness of *Cimicifuga racemosa* (black cohosh) for the symptoms of menopause. *Journal of women's health* 1998, 7(5): 525-529

Liu J, Burdette JE, Xu H, Gu C, van Breemen RB [et al.]. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. *Food Chem* 2001, 49: 2472-2479

Löhning AM. Beitrag zur pharmakologischen Charakterisierung von Zubereitungen aus *Cimicifuga racemosa* Nutt., Ranunculaceae. Inaugural dissertation, conclusion. Westfälische Wilhelm-Universität Münster 1999

Löhning A, Verspohl EJ, Winterhoff H. Pharmacological studies on the dopaminergic activity of *Cimicifuga racemosa*. Workshop of the society for medicinal plant research (Gesellschaft für Arzneipflanzenforschung – GA) 1999

Löhning A, Verspohl EJ, Winterhoff H. Pharmacological studies on the central activity of *Cimicifuga racemosa* in mice. 46<sup>th</sup> Annual congress of the Society 1998, Abstract J10

Löhning A, Diel P, Verspohl EJ, Winterhoff H. In vitro studies on the estrogenic and dopaminergic activity of *Cimicifuga racemosa*. *N-S Arch Pharmacol* 1999, 311: 359

Low Dog T, Powell KL, Weismann SW. Critical evaluation of the safety of *Cimicifuga racemosa* in menopause symptom relief. *Menopause* 2003, 10(4): 299-313

Lundström E, Christow A, Kersemaekers W, Svane G, Azavedo E [et al.]. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. *Amer J Obstet Gynecol* 2002, 186(4): 717-722

Lupu R, Mehmi I, Atlas E, Tsai MS, Pisha E [et al.]. Black cohosh, a menopausal remedy, does not have oestrogenic activity and does not promote breast cancer cell growth. *International Journal of Oncology* 2003, 23: 1407-1412

Maartens LW, Leusink GL, Knottnerus JA, Smeets CG, Pop VJ. Climacteric complaints in the community. *Family Practice* 2001, 18(2): 189-194

Mahady GB, Fabricant D, Chadwick LR, Dietz B. Black cohosh: an alternative therapy for menopause? *Nutr Clin Care* 2002, 5(6): 283-9

Mahady GB. Black Cohosh (*Actaea/Cimicifuga racemosa*) Review of the clinical data for safety and efficacy in menopausal symptoms. *Treat Endocrinol* 2005, 4(3): 177-184

Mahady GB, Low Dog T, Barrett ML, Chavez ML, Gardiner P, Ko R, Marles RJ [et al.]. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. *Menopause* 2008, 15(4): 628-638

Mahady G, Low Dog T, Sarma ND, Giancaspor GI. Suspected black cohosh hepatotoxicity-causality assessment versus safety signal. *Maturitas* 2009, 64: 139-140

Melchert F, Schmidt-Gollwitzer K, Machens K. Hormonsubstitution (HRT) im Klimakterium. Wischnik, Kompendium Gynäkologie und Geburtshilfe 7. Erg.-Lfg. 12/04, IV-4

Menopause. Position Statement: treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. *Menopause* 2004, 11(1): 11-33

MHRA. Black Cohosh; UK Public Assessment Report. Available at:  
<http://www.mhra.gov.uk/home/groups/es-herbal/documents/websiteresources/con2024279.pdf>

MHRA. Menoherb film-coated tablets. Available at:  
<http://www.mhra.gov.uk/home/groups/1-unit1/documents/websiterecources/con2032094.pdf>

- Naser B. Placebo-controlled trial shows no effects of an isopropanolic black cohosh extract on liver function. The Am College of Obstetricians and Gynecologists Poster Sessions (2009), Poster No 64
- Nasr A. Influence of black cohosh (*Cimicifuga racemosa*) use by postmenopausal women on total hepatic perfusion and liver functions. *Fertil Steril* 2009, 92(5): 1780-1782
- Nelson H, Vesco KK, Haney E, Fu R, Nedrow A [et al.]. Nonhormonal therapies for menopausal hot flashes. Systemic review and meta-analysis. *JAMA* 2006, 295(17): 2057-2071
- Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation of hormone replacement therapy. *Maturitas* 2006, 53: 356-361
- Nesselhut T, Liske E. Non-interventional study 1999 Remifemin®. Scientific brochure 1999 Remifemin, 26-27
- Nesselhut T, Bodinet C, Schneider. Verwendung eines Extraktes aus *Cimicifuga racemosa*. Patent cimicifuga 2001 (EP 0847755)
- Nisbet BC, O'Connor RE. Black cohosh-induced hepatitis. *Del Med Jrl* 2006, 79(11): 441-444
- Nißein T, Freudenstein J. Synergistic effects of black Cohosh and Tamoxifen in an animal model of mammary carcinoma. *Maturitas* 2003, 44: 83-166
- Nißein T, Freudenstein J. Prepubertal treatment with black cohosh attenuates pathogenicity in the DMBA rat model of mammary carcinoma. *Climacteric* 2002, 6-8
- Nißein T, Freudenstein J. Effects of an isopropanolic extract of *Cimicifuga racemosa* on urinary crosslinks and other parameters of bone quality in an ovariectomized rat model of osteoporosis. *Journal of Bone and Mineral metabolism* 2003, 21: 370-376
- Nißein T, Koetter U, Freudenstein J. In vitro binding of an isopropanolic extract of black cohosh to selected central nervous receptors. *Maturitas* 2006, P03.02
- Nißein T, Freudenstein J. Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma. *Planta Med* 2007, 73: 318-322
- Nuntanakon P, Jiang B, Einbond LS, Yang H, Kronenberg F [et al.]. Polyphenolic constituents of *Actaea racemosa*. *Journal of natural Products* 2006, 69: 314-318
- O'Connor AM, Merel NH, Te HS, Cohen SM. A case of autoimmune hepatitis associated with the use of black cohosh. *AJG* 2003, Abstract 5165
- Omer-Adam MA, Zieg H, Volk RB, Bodiner C, Liske E. Quantification of characteristic marker substances in various *Cimicifuga racemosa* products and evaluation of their effects on MCF-7 cell proliferation. *Planta Med* 2008, 74: 214
- Osmers R, Kraft K. Phytotherapie bei Wechseljahrsbeschwerden. *Pharm Unserer Zeit* 2004, 33(5): 384-391
- Overk CR, Yao P, Chen S, Deng S, Imai A [et al.]. High-content screening and mechanism-based evaluation of estrogenic botanical extracts. *Combinatorial Chemistry & High Throughput Screening* 2008, 17: 283-293
- Peng L, Wang B, Ren P. Reduction of MTT by flavanoids in the absence of cells. *Colloids and Surfaces B* 2005, 45: 108-111

Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW [et al.]. Novel insights in dopamine receptor physiology. *European Journal of Endocrinology* 2007, 156: 13-21

Powell SL, Gödecke T, Nikolic D, Chen SN, Ahn S [et al.]. In vitro serotonergic activity of black cohosh and identification of Na-Methylserotonin as a potential active constituent. *Journal of Agricultural and Food Chemistry* 2008, 56: 11718-11726

Reame NE, Lukacs JL, Padmanabhan V, Eyvazzadeh AD, Smith YR [et al.]. Black cohosh has central opioid activity in postmenopausal women: Evidence from naloxone blockade and positron emission tomography neuroimaging. *Menopause* 2008, 15(5): 832-840

Reed SD, Ludmann EJ, Newton KM, Grothaus LC, LaCrois AZ [et al.]. Depressive symptoms and menopausal burden in the midlife. *Maturitas* 2009, 62: 306-310

Rhyu MR, Lu J, Webster DE, Fabricant DS, Farnsworth NR [et al.]. Black cohosh (*Actaea racemosa*, *Cimicifuga racemosa*) behaves as a mixed competitive ligand and partial agonist at the human mu opiate receptor. *J Agric Food Chem* 2006, 54(26): 9852-9857

Rice S, Amon A, Whitehead SA. Ethanolic extracts of black cohosh (*Actaea racemosa*) inhibit growth and oestradiol synthesis from oestrone sulphate in breast cancer cells. *Maturitas* 2007, 56: 359-367

Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S [et al.]. Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. *Hepatology* 2008, 48(4): 1175-1183

Rotem C, Kaplan B. Phyto-female complex for the relief of hot flashes, night sweats and quality of sleep: Randomized, controlled, double-blind pilot study. *Gynecological Endocrinology* 2007, 23(2): 117-122

Schulz V. Wechseljahresbeschwerden: Verwirrende US-Studie stellt Wirksamkeit von Cimicifugawurzel-Extrakt infrage. *Zeitschrift für Phytotherapie* 2007, 28: 73-75

Shoemaker M, Cohen I, Campbell M. Reduction of MTT by aqueous herbal extracts in the absence of cells. *Journal of Ethnopharmacology* 2004, 93: 381-384

Shuster J. Black cohosh root? Chasteberry tree? Seizures! *Hospital Pharmacy* 1996, 31(12): 1553-1554

Sluijs van der CP, Bensoussan A, Chang S, Baber R. A randomized placebo-controlled trial on the effectiveness of an herbal formula to alleviate menopausal vasomotor symptoms. *Menopause* 2009, 16(2): 336-344

Stromeier S, Teigeler T, Nahrstedt A. Effects on proliferation of MCF-7-cells by phenolic compounds from the rhizomes of *Cimicifuga racemosa* (L.) Nutt. WWU Münster 2003

Stromeier S, Petereit F, Nahrstedt A. Phenolic esters from the rhizomes of *Cimicifuga racemosa* do not cause proliferation effects in MCF-7 Cells. *Planta Med* 2005, 71: 495-500

Stute P, Nisslein T, Götte M, Kamischke A, Kiesel L [et al.]. Effects of black cohosh on estrogen biosynthesis in normal breast tissue in vitro. *Maturitas* 2007, 57: 382-391

Talorete TPN, Bouaziz M, Sayadi S, Isoda H. Influence of medium type and serum on MTT reduction by flavonoids in the absence of cells. *Cytotechnology* 2006, 52: 189-198

Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W [et al.]. Suspected black cohosh hepatotoxicity – challenges and pitfalls of causality assessment. *Maturitas* 2009, 63: 1-13

Teschke R. Hepatotoxicity by drugs and dietary supplements: safety perspectives on clinical and regulatory issues. *Annals of Hepatology* 2009, 8: 184-195

Thomsen M, Schmidt M. Hepatotoxizität durch *Cimicifuga racemosa*? *Zeitschrift für Phytotherapie* 2003, 24: 11-14

Viereck V, Emons G, Wuttke W. Black cohosh: just another phytoestrogen? *Trends in Endocrinology and Metabolism* 2005, 16(5): 214-221

Wang X, Ge J, Wang K, Qian J, Zou Y. Evaluation of MTT assay for measurement of emodin-induced cytotoxicity. *Assay and Drug Development Technologies* 2006, 4: 2

Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. *MJA* 2002, 177: 432-435

Winterhoff H, Spengler B, Christoffel V, Butterweck V, Löhning A. *Cimicifuga* extract BNO 1055: reduction of hot flushes and hints on antidepressant activity. *Maturitas* 2003, 44(1): 51-58

Woo KC, Park YS, Jung DJ, Lim JO, Baek WY [et al.]. Phytoestrogen cimicifugoside-mediated inhibition of catecholamine secretion by blocking nicotinic acetylcholine receptor in bovine adrenal chromaffin cells. *The Journal of Pharmacology and Experimental Therapeutics* 2004, 309(2): 641-649

Workshop on the Safety of Black Cohosh in Clinical Studies. National Institutes of Health, Bethesda, Maryland, November 22, 2004

Wuttke W, Jarry H, Becker T, Schultens A, Christoffel V [et al.]. Phytoöstrogene – eine Alternative zur Standardhormonersatztherapie? *Der Gynäkologe* 2002, 35: 1007-1020

Wuttke W, Jarry H, Becker T, Schultens A, Christoffel V [et al.]. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? *Maturitas* 2003, 44: 9-20

Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G. Antiestrogenic activities of *Cimicifuga racemosa* extracts. *Journal of Steroid Biochemistry & Molecular Biology* 2002, 80: 125-130